TSRI Anti-Heroin Vaccine Found Effective in Non-Human Primates

TSRI Anti-Heroin Vaccine Found Effective in Non-Human Primates LA JOLLA, CA June 6, 2017 A vaccine developed at The Scripps Research Institute (TSRI) to block the high of heroin has proven effective in non-human primates. This is the first vaccine against an opioid to pass this stage of preclinical testing.

This validates our previous rodent data and positions our vaccine in a favorable light for anticipated clinical evaluation, said study leader Kim Janda, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI.

This research was published recently in the Journal of the American Chemical Society. The primate experiments were led by researchers at Virginia Commonwealth University.

The new research was led by first author Paul Bremer and senior author Kim Janda of The Scripps Research Institute. (Photo by Faith Hark.)

The vaccine works by exposing the immune system to a part of the heroin molecule's telltale structure. This teaches the immune system to produce antibodies against heroin and its psychoactive products. The antibodies neutralize heroin molecules, blocking them from reaching the brain to cause a feeling of euphoria.

Researchers believe that blocking the high of heroin will help eliminate the motivation for many recovering addicts to relapse into drug use. In recent years, public health officials around the world have labeled heroin use as an epidemic.

The Janda Laboratory at TSRI has been working on their heroin vaccine for over eight years; the researchers had previously tested vaccine candidates under laboratory conditions and in rodents, where the strategy proved effective for neutralizing heroin.

For the new study in rhesus monkeys, the researchers redesigned their vaccine candidate to more closely resemble heroin, with the goal of better stimulating the immune system to attack this opioid.

The researchers found that the four primates that were given three doses of this vaccine showed an effective immune response and could neutralize varying doses of heroin. This effect was most acute in the first month after vaccination but lasted for over eight months. The researchers also found no negative side effects from the vaccine.

We believe this vaccine candidate will prove safe for human trials, Janda said. He pointed out that the components of the vaccine have either already been approved by the FDA or have passed safety tests in previous clinical trials.

Interestingly, two of the four primates tested had been pre-vaccinated with the same vaccine candidate for a more basic pilot study seven months prior to the experiment in this study. The researchers found that these two primates showed a much higher response to the vaccine in the second round of experiments. This suggested their antibody-producing cells held an immunological memory of the vaccine. If this effect holds true in humans, a recovering addict would have long-term immunity to heroin.

We were really encouraged to see the vaccine produce such lasting effects in non-human primate models, said Bremer.

This is the first vaccine against heroin to succeed in primate models. Vaccines against other drugs of abuse have been tested in humans without first completing non-human primate trials and failed. Bremer said the new heroin vaccine is different because the researchers took a closer look at the chemistry of the vaccine, studying how well antibodies elicited by the vaccine could bind to drug molecules. These steps let us put our best foot forward when we went into the primate study, Bremer said.

The researchers noted that this vaccine candidate works only against heroin and not other opioid-based pain killers or medications for treating opioid addiction or overdose, leaving those open for use in emergency medical situations and for prescription medicines and substance use disorders.

The next step in this research will be to license the vaccine to an outside company for partnering in clinical trials.

In addition to Janda and Bremer, authors of the study, Development of a Clinically Viable Heroin Vaccine, were Bin Zhou of TSRI; and Joel E. Schlosburg, Matthew L. Banks, Floyd F. Steele and Justin L. Poklis of Virginia Commonwealth University.

The study was supported by the National Institutes of Health (grants UH2DA041146, R01DA026625, K99DA037344 and F31DA037709) and the Skaggs Institute for Chemical Biology.

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the worlds largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine work toward their next discoveries. The institutes graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs. For more information, see www.scripps.edu.

# # #

For information:

Office of Communications

Tel: 858-784-2666

Fax: 858-784-8118

press@scripps.edu

LINK:	http://www.scripps.edu/news/press/2017/20170606janda.html...
	See more stories from scripps

Most recent headlines